Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 1; 2ФГБНУ «Научный центр психического здоровья». 115522, Россия, Москва, Каширское ш., д. 34; 3ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н.Блохина» Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23 makkeycarpediem@mail.ru
Список исп. литературыСкрыть список 1. Airley R. Cancer chemotherapy: Basic Science to the Clinic. Chichester, UK: Wiley-Blackwell, 2009. 2. Dropcho EJ. Neurotoxicity of cancer chemotherapy. Semin Neurol 2004; 24 (4): 419–26. 3. Dietrich J, Norden AD, Wen PY. Emerging antiangiogenic treatments for gliomas – efficacy and safety issues. Curr Opin Neurol 2008; 21 (6): 736–44. 4. Семенова А.И. Кардио- и нейротоксичность противоопухолевых препаратов (патогенез, клиника, профилактика, лечение). Практическая онкология. 2009; 10 (3). / Semenova A.I. Kardio- i neirotoksichnost' protivoopukholevykh preparatov (patogenez, klinika, profilaktika, lechenie). Prakticheskaia onkologiia. 2009; 10 (3). [in Russian] 5. Silberfarb PM, Philibert D, Levine PM. Psychosocial aspects of neoplastic disease: II. Affective and cognitive effects of chemotherapy in cancer patients. Am J Psychiatry 1980; 137 (5): 597–601. 6. Van Dam FS, Schagen SB, Muller MJ et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998; 90 (3): 210–8. 7. Bender CM, Merriman JD. Cancer- and Treatment-Related Cognitive Changes: What Can We Do Now? What Lies Ahead? Oncology (Williston Park) 2014; 28 (9): 201379. 8. Blesch KS, Paice JA, Wickham R et al. Correlates of fatigue in people with breast or lung cancer. Oncol Nurs Forum 1991; 18 (1): 81–7. 9. Pascal JP, Morrow GR, Roscoe JA et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy. Cancer 2010; 116 (14): 3513–20. 10. Priestman TJ. Cancer chemotherapy in clinical practice. Springer, 2008. 11. Sprauten M, Haugnes HS, Brydøy M et al. Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factors. Ann Oncol 2015; 26 (10): 2133–40. 12. Berger AM, Hertzog M, Geary CR et al. Circadian rhythms, symptoms, physical functioning, and body mass index in breast cancer survivors. J Cancer Surviv 2012; 6 (3): 305–14. 13. Savard J, Liu L, Natarajan L et al. Breast cancer patients have progressively impaired sleep-wake activity rhythms during chemotherapy. Sleep 2009; 32 (9): 1155–60. 14. Liu L, Rissling M, Neikrug A et al. Fatigue and Circadian Activity Rhythms in Breast Cancer Patients Before and After Chemotherapy: A Controlled Study. Fatigue 2013; 1 (1–2): 12–26. 15. Roscoe JA, Morrow GR, Hickok JT et al. Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment. Support Care Cancer 2002; 10 (4): 329–36. 16. Altmaier EM, Ross WE, Moore K. A pilot investigation of the psychologic functioning of patients with anticipatory vomiting. Cancer 1982; 49 (1): 201–4. 17. Coons HL, Leventhal H, Nerenz DR et al. Anticipatory nausea and emotional distress in patients receiving cisplatin-based chemotherapy. Oncol Nurs Forum 1987; 14 (3): 31–5. 18. Lyles JN, Burish TG, Krozely MG, Oldham RK. Efficacy of relaxation training and guided imagery in reducing the aversiveness of cancer chemotherapy. J Consult Clin Psychol 1982; 50 (4): 509–24. 19. Morrow GR. Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients. J Natl Cancer Inst 1982; 68 (4): 585–8. 20. Aapro MS, Grunberg SM, Manikhas GM et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006; 17 (9): 1441–9. 21. Hesketh PJ, Grunberg SM, Herrstedt J et al. Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 2006; 14 (4): 354–60. 22. Chelkeba L, Gidey K, Mamo A et al. Olanzapine for chemotherapy-induced nausea and vomiting: systematic review and meta-analysis. Pharm Pract (Granada) 2017; 15 (1): 877. 23. Nesse RM, Carli T, Curtis GC, Kleinman PD. Pretreatment nausea in cancer chemotherapy: a conditioned response? Psychosom Med 1980; 42 (1): 33–6. 24. Nerenz DR, Leventhal H, Love RR. Factors contributing to emotional distress during cancer chemotherapy. Cancer 1982; 50 (5): 1020–7. 25. Redd WH, Andresen GV, Minagawa RY. Hypnotic control of anticipatory emesis in patients receiving cancer chemotherapy. J Consult Clin Psychol 1982; 50 (1): 14–9. 26. Redd WH, Andrykowski MA. Behavioral intervention in cancer treatment: controlling aversion reactions to chemotherapy. J Consult Clin Psychol 1982; 50 (6): 1018–29. 27. Mercadante S, Masedu F, Balzani I et al. Prevalence of delirium in advanced cancer patients in home care and hospice and outcomes after 1 week of palliative care. Support Care Cancer 2018; 26 (3): 913–9. 28. Weinrich S, Sarna L. Delirium in the older person with cancer. Cancer 1994; 74 (Suppl. 7): 2079–91. 29. Stiefel F, Holland J. Delirium in cancer patients. Int Psychogeriatr 1991; 3 (2): 333–6. 30. Caraceni A. Drug-associated delirium in cancer patients. EJC (Suppl.) 2013; 11 (2): 233–40. 31. Küpfer A, Aeschlimann C, Cerny T. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol 1996; 50 (4): 249–52. 32. Schellekens AF, Mulder SF, van Eijndhoven PF et al. Psychotic symptoms in the course of sunitinib treatment for advanced renal cell cancer. Two cases. Gen Hosp Psychiatry 2011; 33 (1): 83. e1–3. 33. Hernández R, Juan O, Alberola V. Ifosfamide-induced psychosis. Acta Oncol 2004; 43 (1): 119–20. 34. Fora A, Alabsi E, Fakih M. A case of 5-fluorouracil-induced acute psychosis. Clin Colorectal Cancer 2009; 8 (3): 166–8. 35. Celano CM, Freudenreich O, Fernandez-Robles C et al. Depressogenic effects of medications: a review. Dialogues Clin Neurosci 2011; 13 (1): 109–25. 36. Cohen MH, Johnson JR, Wang YC et al. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 2005; 10 (6): 363–8. 37. Haskell CM, Canellos GP, Leventhal BG et al. L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med 1969; 281 (19): 1028–34. 38. Oettgen HF, Stephenson PA, Schwartz MK et al. Toxicity of E.coli L-asparaginase in man. Cancer 1970; 25 (2): 253–78. 39. Musselman DL, Lawson DH, Gumnick JF et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344 (13): 961–6. 40. Kirkwood JM, Bender C, Agarwala S et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 2002; 20 (17): 3703–18. 41. Hauschild A, Gogas H, Tarhini A et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 2008; 112 (5): 982–94. 42. Greenberg DB, Jonasch E, Gadd MA et al. Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. Cancer 2000; 89 (2): 356–62. 43. Islam M, Frye RF, Richards TJ et al. Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin Cancer Res 2002; 8 (8): 2480–7.